– Phase 1B portion of Phase 1B/2 study demonstrated preliminary CR/CRi rate of 33% (n=6)
– Annamycin has Fast Track Status and Orphan Drug Designation from FDA for the treatment of AML
Read more at prnewswire.comMoleculin Doses First Subjects in Phase 2 Portion of Clinical Trial Evaluating Annamycin in Combination with Cytarabine (Ara-C) for the Treatment of Acute Myeloid Leukemia (AML)
PR Newswire -
Mon Oct 2, 2023
Columnist
Contributor Content
Press Release
Sponsored Content
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here
This article could contain syndicated content. We have not reviewed, approved, or endorsed the content and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here
/A%20Palantir%20office%20building%20in%20Tokyo_%20Image%20by%20Hiroshi-Mori-Stock%20via%20Shutterstock_.jpg)
/Super%20Micro%20Computer%20Inc%20logo%20on%20phone%20and%20stock%20data-by%20Poetra_RH%20via%20Shutterstock.jpg)
/Palantir%20by%20rblfmr%20via%20Shutterstock.jpg)